The global market for Gene Therapy is estimated at US$1.4 Billion in 2023 and is projected to reach US$6.0 Billion by 2030, growing at a CAGR of 23.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the gene therapy market is driven by several factors, including significant advancements in genetic research and biotechnological techniques. The increasing prevalence of genetic disorders and high unmet need for novel treatments in oncology, neurology, and rare diseases are major market drivers. The successful commercialization of several gene therapies in recent years has demonstrated the potential for substantial returns on investment, attracting more funding for research and development in this field. Additionally, regulatory incentives, such as orphan drug designations and accelerated approvals, encourage the development of gene therapies for rare and severe conditions.
Consumer behavior, particularly the growing demand for personalized medicine and treatments that offer durable to permanent cures, also propels the market forward. Moreover, collaborations between biotech firms, pharmaceutical companies, and academic institutions are fostering innovation and speeding the translation of gene therapy from research to clinical settings. These factors, combined with the increasing global capacity for biopharmaceutical manufacturing, ensure continued growth and expansion of gene therapy solutions, making it one of the most dynamic and transformative fields in modern medicine.
The growth in the gene therapy market is driven by several factors, including significant advancements in genetic research and biotechnological techniques. The increasing prevalence of genetic disorders and high unmet need for novel treatments in oncology, neurology, and rare diseases are major market drivers. The successful commercialization of several gene therapies in recent years has demonstrated the potential for substantial returns on investment, attracting more funding for research and development in this field. Additionally, regulatory incentives, such as orphan drug designations and accelerated approvals, encourage the development of gene therapies for rare and severe conditions.
Consumer behavior, particularly the growing demand for personalized medicine and treatments that offer durable to permanent cures, also propels the market forward. Moreover, collaborations between biotech firms, pharmaceutical companies, and academic institutions are fostering innovation and speeding the translation of gene therapy from research to clinical settings. These factors, combined with the increasing global capacity for biopharmaceutical manufacturing, ensure continued growth and expansion of gene therapy solutions, making it one of the most dynamic and transformative fields in modern medicine.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Viral Gene Therapy segment, which is expected to reach US$5.5 Billion by 2030 with a CAGR of a 23.3%. The Non-Viral Gene Therapy segment is also set to grow at 20.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $748.7 Million in 2023, and China, forecasted to grow at an impressive 29.5% CAGR to reach $216.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Gene Therapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Gene Therapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Gene Therapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Amgen, Inc., Alnylam Pharmaceuticals, Inc., Bionomics Ltd., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 154 Featured):
- Amgen, Inc.
- Alnylam Pharmaceuticals, Inc.
- Bionomics Ltd.
- BioMarin Pharmaceutical, Inc.
- AnGes, Inc.
- Amicus Therapeutics, Inc.
- Arrowhead Pharmaceuticals, Inc.
- bluebird bio, Inc.
- Advantagene, Inc.
- Biogen, Inc.
- Abeona Therapeutics
- Aptah
- Avrobio
- Arbor Biotechnologies, Inc.
- Biocardia, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET
NON-VIRAL VECTORS TO WITNESS FASTER GROWTH
WORLD BRANDS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen, Inc.
- Alnylam Pharmaceuticals, Inc.
- Bionomics Ltd.
- BioMarin Pharmaceutical, Inc.
- AnGes, Inc.
- Amicus Therapeutics, Inc.
- Arrowhead Pharmaceuticals, Inc.
- bluebird bio, Inc.
- Advantagene, Inc.
- Biogen, Inc.
- Abeona Therapeutics
- Aptah
- Avrobio
- Arbor Biotechnologies, Inc.
- Biocardia, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 411 |
| Published | April 2025 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.4 Billion |
| Forecasted Market Value ( USD | $ 6 Billion |
| Compound Annual Growth Rate | 23.1% |
| Regions Covered | Global |
